Immune Related Adverse Events Low and Moderate Grade Adverse Events Increase Odds of Treatment Discontinuation in Hematologic Malignancies Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab Adverse Events Incidence Rates